SCHEMBL10061639

SCHEMBL10061639

CNC(C)c1cccc(N)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.46
CYP3A4 P08684 6/20 0.44
CASP1 P29466 1/20 0.44
RECQL P46063 1/20 0.44
KRAS P01116 1/20 0.42
SOS1 Q07889 1/20 0.42
CYP2D6 P10635 4/20 0.41
SLC6A2 P23975 3/20 0.41
SLC6A4 P31645 3/20 0.41
SLC6A3 Q01959 3/20 0.41
KCNH2 Q12809 2/20 0.41
AURKA O14965 1/20 0.41
RPS6KB1 P23443 1/20 0.41
ALDH1A1 P00352 3/20 0.40
CPN1 P15169 1/20 0.40
CPB2 Q96IY4 1/20 0.40
CHRM2 P08172 1/20 0.39
ADRA1A P35348 1/20 0.39
RGS12 O14924 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31226606 1.00 MAPKAPK2 (0.46) MAPKAPK2CYP3A4CASP1RECQLKRAS
SCHEMBL31413927 0.82 MAPKAPK2 (0.44) MAPKAPK2CYP3A4CASP1RECQLKRAS
SCHEMBL17463843 0.79 CYP3A4 (0.44) MAPKAPK2CYP3A4CASP1RECQLCYP2D6
SCHEMBL19176016 0.78 HDAC4 (0.44) CYP3A4CYP2D6ALDH1A1CHRM2ADRA1A
SCHEMBL104340 0.78 CYP3A4 (0.52) MAPKAPK2CYP3A4CASP1RECQLALDH1A1
SCHEMBL30349751 0.78 CYP3A4 (0.52) MAPKAPK2CYP3A4CASP1RECQLALDH1A1
SCHEMBL272384 0.78 CYP3A4 (0.52) MAPKAPK2CYP3A4CASP1RECQLCYP2D6
SCHEMBL27605679 0.77 MAPKAPK2 (0.51) MAPKAPK2CYP3A4CASP1RECQLKRAS
SCHEMBL20828069 0.77 ACHE (0.46) MAPKAPK2CYP3A4SOS1CYP2D6SLC6A2
SCHEMBL2669155 0.77 ACHE (0.46) MAPKAPK2CYP3A4SOS1CYP2D6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207179-B2 Substituted indolines as tyrosine kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-26 US disclosed
US-8207179-B2 Substituted indolines as tyrosine kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-26 US disclosed
US-20100222331-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
US-20100222331-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
WO-2008152014-A2 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222331-A1 NEW COMPOUNDS CCNA1, CCNY, MKI67 MAPKAPK2 3061/4885CYP3A4 1094/4885CASP1 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.